Home > News > Natco Pharma recalls breast cancer drug
July 18th, 2009
Natco Pharma recalls breast cancer drug
Abstract:
Natco Pharma Ltd has recalled its breast cancer drug Albupax following an order from the Drug Controller General of India (DCGI), which said that the drug might cause damage to liver.
The Hyderabad-based company has stopped the production, distribution and marketing of the drug and is in the process of recalling stocks, a company spokesperson told Business Line.
"The product has passed all quality tests. However, on DCGI's instructions, we have stopped marketing the product in the interim.
"We are taking immediate steps to investigate the issue," he said.
Testing procedures
The testing procedures for the drug should also be looked into as Albupax was nanotechnology-based products.
"The testing procedures for this drug are quite complex," he added.
Natco is currently engaged in a legal dispute on patent of Albupax with its original innovator, American Biosciences and is awaiting judgment.
Source:
thehindubusinessline.com
Bookmark:
| Related News Press |
News and information
Simulating magnetization in a Heisenberg quantum spin chain April 5th, 2024
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||